- Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearEli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug…Fierce Biotech · 5d ago↗ source
- Roche Diagnostics growth remains muted amid China headwindsRoche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales.Fierce Biotech · 5d ago↗ source
- Australian biopharma Clinuvel to shed up to 20% of workforce in move to USAustralian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.— but up to a fifth of the company’s workforce won’t be staying for the trans-Pacific pivot.